[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363399-105":59,"doc-detail-363399-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinicopathological-features-and-prognosis-of-her2-low-gastric-cancer-a-real-world-retrospective-cohort-study","Clinicopathological features and prognosis of HER2-low gastric cancer - a real-world retrospective cohort study","","HER2-low expression has emerged as a potential actionable biomarker in gastric cancer, yet its clinical implications and prognostic value remain insufficiently clarified for guiding management in the antibody-drug conjugate era. This real-world retrospective cohort study evaluates clinicopathological characteristics and outcomes among 994 patients categorized by HER2-low versus HER2-zero status, further stratified by non-metastatic and metastatic stages, using survival analyses and multivariable modeling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-features-and-prognosis-of-her2-low-gastric-cancer-a-real-world-retrospective-cohort-study/363399/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-features-and-prognosis-of-her2-low-gastric-cancer-a-real-world-retrospective-cohort-study/363399.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about HER2-low gastric cancer?","Question",{"text":113,"@type":114},"It assesses whether HER2-low expression shows distinct clinicopathological features and can predict patient outcomes compared with HER2-zero gastric cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients grouped in the retrospective cohort?",{"text":118,"@type":114},"Among 994 patients, 248 had HER2-low expression and 746 had HER2-zero expression, and each group was further divided into non-metastatic (M0) and metastatic (M1) subgroups.",{"name":120,"@type":111,"acceptedAnswer":121},"What statistical methods were used to evaluate prognosis and model performance?",{"text":122,"@type":114},"Kaplan–Meier analysis and multivariable Cox regression tested prognostic value, and a nomogram was built and evaluated using C-index, time-dependent ROC curves, AUC, and calibration curves.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363399,1790257489,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Zhang et al. World Journal of Surgical Oncology (2026) 24:201  \n[https://doi.org/10.1186/s12957-026-04323-5](https://doi.org/10.1186/s12957-026-04323-5)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nClinicopathological features and prognosis of HER2-low gastric cancer: a real-world retrospective cohort study  \nHong Zhang1,3†, Yuan Tian1†, Yuan Zhao2, Nannan Huang1, Juan Cao3 and Peifeng Liang4*  \nAbstract  \nBackground HER2-low expression has recently gained considerable attention as an actionable biomarker in gastric cancer (GC) . However, clinical implications of HER2-low expression in GC remains uncertain, which limited its precise management in the era of antibody‒drug conjugates. This study aims to describe the clinicopathological features and its value in predicting outcomes for GC patients.  \nMethod We performed a retrospective study of 994 patients (248 with HER2-low expression and 746 with HER2-zero expression) from January 2018 to December 2023. Each cohort was further divided into non-metastatic (M0) and metastatic (M1) subgroups. Clinicopathological features and survival outcomes were collected and compared between HER2-low and HER2-zero GC. Kaplan–Meier analysis and Multivariable Cox regression analyses were utilized to confirm the prognostic value. Furthermore, a nomogram was established to predict overall survival (OS) rates at 1, 2, and 3 years. The Concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves and calibration curves were utilized to assess the discrimination and reliability of the Model.  \nResults Significant differences were observed in age (≥ 60 years: 65 . 3% vs. 55. 2%, P = 0 . 005) and ethnicity (Hui ethnicity:12 . 5% vs.19.4%, P = 0 . 001) between the HER2-low and HER2-zero GC. HER2-low GC had lower T stage than HER2-zero GC, with T3 stage (21 . 8% vs. 12. 5%) and T4 stage (58 . 1% vs.65.4%) P \u003C 0.05. HER2-low status was identified as an independent prognostic factor associated with worse survival outcomes, particularly in patients with GC at M0 stage (HR 1.420; 95% CI 1.058–1. 907) . The nomogram prediction model was constructed by including these factors at M0 stage. The C-index, AUC value and calibration curves demonstrated that the nomogram performed well in predicting OS at 1, 2, and 3 years.  \nConclusion The findings from the present study demonstrated that patients with HER2-low GC exhibited distinct pathological characteristics and had a worse prognosis. Further research is warranted to refine future diagnostic and treatment strategies for this subgroup.  \nKeywords Gastric cancer, HER2-low, Prognosis, Real-world study, Nomogram, Retrospective cohort study  \n†Hong Zhang and Yuan Tian contributed equally to this work.  \n*Correspondence: Peifeng Liang [doctor_pf@126.com](doctor_pf@126.com)  \n1Public Health Center, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan 750004, Ningxia, China  \n2Department of Medical Records and Statistics, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan 750004, Ningxia, China 3School of Public Health, Ningxia Medical University, Yinchuan 750000, Ningxia, China  \n4Department of Medical Affairs, People’s Hospital of Ningxia Hui Autonomous Region, No. 255 Zhengyuan North Road, Yinchuan, Ningxia 750004, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a cr","cbCairmNaiH8zATu","https://ap.wps.com/l/cbCairmNaiH8zATu","pdf",2540599,13,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n## Gastric cancer epidemiology and unmet need\n## HER2 biology and treatment landscape","[{\"question\":\"What question does the study address about HER2-low gastric cancer?\",\"answer\":\"It assesses whether HER2-low expression shows distinct clinicopathological features and can predict patient outcomes compared with HER2-zero gastric cancer.\"},{\"question\":\"How were patients grouped in the retrospective cohort?\",\"answer\":\"Among 994 patients, 248 had HER2-low expression and 746 had HER2-zero expression, and each group was further divided into non-metastatic (M0) and metastatic (M1) subgroups.\"},{\"question\":\"What statistical methods were used to evaluate prognosis and model performance?\",\"answer\":\"Kaplan–Meier analysis and multivariable Cox regression tested prognostic value, and a nomogram was built and evaluated using C-index, time-dependent ROC curves, AUC, and calibration curves.\"}]","Clinicopathological features and prognosis of HER2-low gastric cancer - a real-world retrospective cohort study | PDF",1790151073,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c171cad05fa979fc9c913a06f9faa1bb.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/664fed83096743ac1b113a1bfc66368a.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/276d533ab5c43eb9d8701bc2cb762a49.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84d52c9575a1517db3fa2f4d8a325dd1.webp",980,1306]